Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EBIT (2020 - 2025)

Insight Molecular Diagnostics' EBIT history spans 6 years, with the latest figure at -$11.0 million for Q3 2025.

  • For Q3 2025, EBIT rose 18.25% year-over-year to -$11.0 million; the TTM value through Sep 2025 reached -$61.3 million, down 40.66%, while the annual FY2024 figure was -$61.0 million, 142.84% down from the prior year.
  • EBIT for Q3 2025 was -$11.0 million at Insight Molecular Diagnostics, down from -$9.8 million in the prior quarter.
  • Across five years, EBIT topped out at $5.8 million in Q1 2023 and bottomed at -$33.6 million in Q4 2024.
  • The 5-year median for EBIT is -$9.8 million (2025), against an average of -$10.1 million.
  • The largest YoY upside for EBIT was 293.9% in 2023 against a maximum downside of 281.77% in 2023.
  • A 5-year view of EBIT shows it stood at -$15.2 million in 2021, then rose by 23.33% to -$11.6 million in 2022, then tumbled by 38.9% to -$16.2 million in 2023, then crashed by 107.84% to -$33.6 million in 2024, then surged by 67.15% to -$11.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's EBIT are -$11.0 million (Q3 2025), -$9.8 million (Q2 2025), and -$6.8 million (Q1 2025).